Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Axsome Therapeutics, Inc. and ACADIA Pharmaceuticals Inc. from 2014 to 2023. Over this period, ACADIA Pharmaceuticals consistently outspent Axsome Therapeutics, with its SG&A expenses peaking at approximately $402 million in 2023, a 23% increase from 2014. In contrast, Axsome Therapeutics saw a dramatic rise in its SG&A expenses, growing from a modest $1.4 million in 2014 to $323 million in 2023, marking an exponential increase of over 23,000%. This surge reflects Axsome's aggressive expansion and investment in its operational capabilities. The data highlights the contrasting strategies of these two companies, with ACADIA maintaining steady growth and Axsome rapidly scaling its operations.